Dr. Gearóid Tuohy

AsciepiX Therapeutics Inc., (New Jersey, US) has announced the dosing of a Phase 1/2a trial of AXT107 for diabetic macular edema (DME).

AsciepiX Therapeutics Inc. has announced the dosing of a Phase 1/2a clinical trial for diabetic macular edema (DME) using an intravitreal “self-forming gel depot peptide”.… Read More »AsciepiX Therapeutics Inc., (New Jersey, US) has announced the dosing of a Phase 1/2a trial of AXT107 for diabetic macular edema (DME).